)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
BioVie
BioVie (BIVI) investor relations material
BioVie Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary11 May, 2026
Executive summary
Focused on developing therapies for neurological, neurodegenerative, and advanced liver diseases, with lead programs in Parkinson's, Alzheimer's, Long COVID, and liver cirrhosis.
Phase 2b Parkinson's trial completed enrollment; topline results expected mid-2026.
Long COVID Phase 2 trial ongoing, funded by a $13.1M DOD grant.
No revenue generated; operations funded by equity raises and grants.
Financial highlights
Net loss for the quarter ended March 31, 2026: $5.3M, up from $2.8M year-over-year.
Net loss for the nine months ended March 31, 2026: $16.4M, up from $14.1M year-over-year.
Operating expenses for the quarter: $5.4M, up from $3.0M year-over-year.
Cash and cash equivalents as of March 31, 2026: $13.1M.
Stockholders' equity as of March 31, 2026: $15.6M.
Outlook and guidance
No revenues expected in the foreseeable future; continued reliance on external financing.
Future operations depend on successful clinical development and ability to secure additional capital.
Substantial doubt exists regarding ability to continue as a going concern.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from BioVie
- Bezisterim targets neuroinflammation and metabolic dysfunction, aiming to improve Parkinson's outcomes.BIVI
KOL event7 May 2026 - Lead therapies show strong efficacy in neurodegeneration and ascites, with high commercial potential.BIVICorporate presentation23 Apr 2026
- Imminent clinical data for Parkinson's and long COVID could unlock major market opportunities.BIVIBiotech Resurgence: Platforms and Pipelines of Today's Innovators16 Apr 2026
- Phase II data for Parkinson's and long COVID expected in 2024; BIV201 phase III planning underway.BIVIStatus update4 Mar 2026
- Net loss narrowed, cash bolstered by $10.5M raise, but going concern risks persist.BIVIQ2 20266 Feb 2026
- Directors elected, auditor ratified, and equity plan amendment approved by strong majority.BIVIAGM 20253 Feb 2026
- All proposals, including director elections and plan amendments, passed with strong approval.BIVIAGM 202415 Jan 2026
- Key clinical trials advance with strong cash runway and major data readouts expected by mid-2026.BIVIInvestor Update29 Dec 2025
- Shareholders will vote on director elections, auditor ratification, say-on-pay, and a major equity plan increase.BIVIProxy Filing2 Dec 2025
Next BioVie earnings date
Q4 202614 Aug, 2026
BioVie
Next BioVie earnings date
Q4 202614 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage